Search

Displaying results 1101 - 1110 of 1915 in total
  1. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet.

  2. Drug

    Haloprogin

    go.drugbank.com/drugs/DB00793
    ApprovedWithdrawn

    Haloprogin is no longer available in the United States and has been discontinued.

  3. Drug

    Talniflumate

    go.drugbank.com/drugs/DB09295
    Investigational

    Talniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) [L1405].

  4. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) th...

  5. Drug

    Nerinetide

    go.drugbank.com/drugs/DB12595
    Investigational

    Na 1 is under investigation in clinical trial NCT00728182 (Evaluating Neuroprotection in Aneurysm Coiling Therapy).

    Synonyms: Na-1
  6. Drug

    Fosgemcitabine palabenamide

    go.drugbank.com/drugs/DB15057
    Investigational

    NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).

    Synonyms: L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester
  7. Drug

    NC-6300

    go.drugbank.com/drugs/DB17341
    Experimental

    NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.

    Synonyms: NC-6300
  8. Drug

    PRG-A01

    go.drugbank.com/drugs/DB18613
    Investigational

    PRG-A01 is a novel inhibitor of Cu, Zn-superoxide dismutase (SOD1) misfolding and aggregation.

  9. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA...

  10. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a ne...